Is amiodarone contraindicated in patients with clinically significant bradycardia (e.g., sinus rate <50 bpm, sinus pause >2 seconds, second‑ or third‑degree atrioventricular block) unless a permanent pacemaker is in place?

Is Amiodarone Contraindicated in Bradycardia?

Yes, amiodarone is absolutely contraindicated in patients with marked sinus bradycardia, second-degree, or third-degree atrioventricular (AV) block unless a functioning permanent pacemaker is already in place. 1

Absolute Contraindications from FDA Labeling

The FDA drug label explicitly states that amiodarone is contraindicated in patients with:

• Marked sinus bradycardia
• Second-degree AV block (without pacemaker)
• Third-degree AV block (without pacemaker)
• Cardiogenic shock 1

This is a black-and-white contraindication—not a relative concern or a "use with caution" scenario. If your patient has clinically significant bradycardia or high-grade AV block and no pacemaker, amiodarone should not be initiated.

Clinical Context: Why This Matters

Bradycardia Risk Profile

Amiodarone causes bradycardia and heart block in 1-3% of patients during oral therapy 2 and in 4.9% during IV administration 1. The drug can precipitate:

• Progressive sinus node dysfunction
• Worsening AV block (second or third-degree)
• Symptomatic bradycardia requiring permanent pacemaker implantation 3, 4, 5, 3

Critical point: Amiodarone-associated bradycardia requiring permanent pacemaker is more frequent than with other antiarrhythmics and occurs more commonly in women than men 3, 4, 5, 3.

Pre-existing Conduction Disease Amplifies Risk

Patients with pre-existing conduction disorders have a 24% incidence of developing symptomatic bradycardia on amiodarone 6. This includes those with:

• First-degree AV block
• Bundle branch blocks (right or left)
• Sinus node dysfunction (even if previously asymptomatic)

In contrast, patients without baseline conduction abnormalities had zero cases of symptomatic bradycardia in the same study 6.

Dose-Dependent Risk

The risk is dose-dependent and time-dependent:

• Daily doses >200 mg increase risk 2-fold (HR 2.0) 7
• Risk is highest during the first 90 days of treatment (5.2% per person-year) 7
• In elderly patients with atrial fibrillation and prior MI, amiodarone increases pacemaker risk 2.14-fold overall, and 3.86-fold in women 8

Practical Algorithm for Decision-Making

Before Starting Amiodarone:

1. Screen for conduction disease:

   • Obtain baseline ECG
   • Measure PR interval, QRS duration, QT interval
   • Document baseline heart rate and rhythm
   • Check for sinus pauses >2 seconds on monitoring

2. Identify absolute contraindications:

   • Marked sinus bradycardia (generally <50 bpm with symptoms)
   • Second-degree Mobitz II AV block
   • High-grade (2:1) AV block
   • Third-degree (complete) AV block
   • If any present WITHOUT pacemaker → DO NOT give amiodarone 1

3. Assess relative risk factors:

   • First-degree AV block
   • Bundle branch block
   • Asymptomatic sinus node dysfunction
   • Female gender (higher risk)
   • Age >65 years
   • If present → Consider prophylactic pacemaker or alternative therapy

If Bradycardia Develops During Treatment:

Per pediatric emergency guidelines (principles apply to adults) 9:

• Slow or stop the infusion immediately
• Consider temporary pacing if symptomatic
• Do not resume without pacemaker if second/third-degree block develops

The FDA label warns that bradycardia may be progressive and terminal despite interventions 1. In controlled trials, one patient died from progressive bradycardia despite treatment measures.

Special Populations

Patients Requiring Both Amiodarone and Rate Control

When amiodarone is initiated in patients already on AV nodal blocking agents (beta-blockers, calcium channel blockers, digoxin):

• Reduce doses of rate-control medications when heart rate slows 3, 4, 5, 3
• Stop rate-control drugs if excessive slowing occurs 3
• Monitor heart rate weekly during loading phase 3, 5
• Consider prophylactic pacemaker if multiple bradycardic agents are necessary 10

Atrial Fibrillation Patients

For AF patients with conduction disease who need rhythm control:

• Amiodarone can be used only if pacemaker is in place for second/third-degree block 9
• Recent evidence suggests that "drug-related AVB" is rarely truly reversible—early permanent pacing is recommended rather than waiting for drug washout 11
• This is particularly important in frail elderly patients where delays in pacing increase morbidity 11

Common Pitfalls to Avoid

1. Assuming bradycardia is "just a side effect": High-grade AV block on amiodarone is a contraindication to continuing the drug without pacemaker protection 1

2. Waiting for "reversibility": The traditional teaching that drug-induced AVB is reversible is increasingly questioned. Recurrence rates are high, and true drug-induced AVB is rare 11

3. Underestimating risk in women: Female patients have 2.5-fold higher risk of amiodarone-induced bradycardia requiring pacemaker 8

4. Missing baseline conduction disease: Always obtain ECG before starting amiodarone. A first-degree AV block or bundle branch block increases risk 24% 6

5. Using high loading doses: Doses >200 mg daily significantly increase bradycardia risk 7. Start low, especially in elderly patients.

Bottom Line

Amiodarone is absolutely contraindicated in marked sinus bradycardia and second/third-degree AV block without a pacemaker. This is not negotiable per FDA labeling 1. For patients with lesser degrees of conduction disease (first-degree block, bundle branch block), amiodarone carries substantial risk (up to 24%) of symptomatic bradycardia 6, and prophylactic pacemaker placement should be strongly considered before initiating therapy, particularly in elderly patients, women, and those requiring concomitant AV nodal blocking agents.